- Also known as
- MT-I · MT1 · Melanotan 1 · afamelanotide · NDP-MSH · [Nle4, D-Phe7]-α-MSH
- Class
- Melanocortin-1 receptor agonist (linear alpha-MSH analogue)
- Form
- Powder, lyophilised, in 10 mg vials
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
- Molecular weight
- 1646.9 g/mol
What is Melanotan I?
In the literature Melanotan I is categorised as a melanocortin-1 receptor agonist (linear alpha-MSH analogue), with a molecular weight of 1646.9 g/mol. Several spellings refer to the identical material, among them MT-I, MT1 and Melanotan 1. Its recorded sequence, Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, is linear rather than cyclic like Melanotan II. Research reported on it spans rat, human and cell-culture models, and among the 8 studies set out below just one is a controlled human trial. Borealis Peptides keeps it in 10 mg vials of lyophilised powder intended for in-vitro laboratory research. It carries no medicinal authorization and must not be used in any living subject.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Langendonk JG et al.2015 · N Engl J Med · PMID 26132941 | Human, two randomised double-blind placebo-controlled trials in erythropoietic protoporphyria (EU n=74, US n=94) | Afamelanotide 16 mg subcutaneous implant (Scenesse formulation) or placebo, every 60 days | 180 days (US, 3 implants) and 270 days (EU, 5 implants) | Median pain-free time in direct sunlight was longer with afamelanotide (US 69.4 vs 40.8 hours, P=0.04; EU 6.0 vs 0.8 hours, P=0.005), and the EU trial recorded fewer phototoxic reactions (77 vs 146). Adverse events were mostly mild. |
| Lengweiler S et al.2015 · Skin Pharmacol Physiol · PMID 25402764 | Human, erythropoietic protoporphyria patients in phase II/III trials (n=26), antibody assay | Not stated in the abstract (afamelanotide, Scenesse) | Up to 6 years of exposure | A new ELISA found no anti-drug antibodies in 23 of 26 patients. Three had pre-existing immunoreactivity to afamelanotide and alpha-MSH, and their titres did not change during treatment. |
| Böhm M et al.2014 · J Eur Acad Dermatol Venereol · PMID 22845050 | Human, phase II open-label pilot in acne vulgaris (n=3) | Afamelanotide 16 mg subcutaneous sustained-release resorbable implant | Assessed 56 days after the first implant | Total and inflammatory acne lesion counts fell in all 3 patients and quality-of-life scores improved. All 3 showed increased pigmentation, mainly on the face. |
| Biolcati G et al.2014 · Clin Exp Dermatol · PMID 24256215 | Cell culture (Hailey-Hailey lesion keratinocytes) plus human open-label pilot (n=2) | Patients: afamelanotide 16 mg subcutaneous sustained-release resorbable implant; cell dose not stated in the abstract | Assessed 30 and 60 days after the first implant | In lesion-derived keratinocytes, afamelanotide upregulated Nrf2 and restored defective proliferation. Both patients had 100% clearance of lesions at 60 days. |
| Lonati C et al.2021 · Peptides · PMID 33865932 | Rat, ex vivo lung perfusion after ischaemia/reperfusion or cardiac death (N=10 per protocol, 5 treated) | Not stated in the abstract (NDP-MSH given before lung procurement and during perfusion) | Not stated in the abstract | NDP-MSH lowered inflammatory mediators, leukocytes and lactate in perfusate, raised ATP in ischaemia/reperfusion lungs and improved vascular and airway measures in cardiac-death lungs. MC1R and MC5R were found in lung tissue. |
| Rennalls LP et al.2010 · Immunology · PMID 20074207 | Cell culture (human dendritic cells) | Not stated in the abstract | Not stated in the abstract | Dendritic cells expressed mRNA for all known melanocortin receptors. NDP-MSH reduced their ability to stimulate allogeneic T cells and lowered surface CD86, ICAM-1 and CD1a. |
| Jiang J et al.1995 · Pigment Cell Res · PMID 8789740 | Cell culture (17 human melanoma cell lines) | Not stated in the abstract | 72 hours, and 6 to 43 days in some lines | Only one melanotic line consistently raised tyrosinase activity. Cell numbers fell sharply in both melanotic and amelanotic lines, and growth inhibition persisted days after the peptide was removed. |
| Frändberg PA et al.1994 · Biochem Biophys Res Commun · PMID 8060302 | Cell culture (COS-7 cells expressing wild-type and mutant human MC1R) | Not applicable (receptor binding assay) | Not applicable | Single alanine mutations at Asp117 or His260 cut alpha-MSH binding affinity by 267-fold and 132-fold, while NDP-MSH affinity was unchanged, pointing to different attachment points for the two agonists. |
What these studies don't show: There is controlled human data, yet its reach is narrow. The people enrolled are a selected group, the measures taken are frequently surrogates rather than real outcomes, and the observation periods are short. None of it applies beyond the trial protocol itself. Confirming that the vial contains what the label states tells you nothing about what the compound actually does.
Every study links to its PubMed record. See all Melanotan I studies in the research library →
Melanotan I price in Canada: 10mg vial
Buy Melanotan I in Canada in a 10mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $43.00 | $4.30/mg |
Starter kit
Is Melanotan I available in Canada?
Canada has no authorized melanotan-1 product. Searching the Drug Product Database for melanotan brings up afamelanotide (SCENESSE, DIN 02569825), a separate molecule entirely. No authorized Melanotan I product therefore exists in Canada. Borealis Peptides provides it as research material for in-vitro laboratory use only. How Health Canada treats research peptides →
Side effects reported in studies
Whatever the cited studies observed about tolerability is reproduced here word for word. Human research on this scale cannot establish a safety profile.
Melanotan I FAQ
What is Melanotan I?
By chemistry Melanotan I falls under melanocortin-1 receptor agonist (linear alpha-MSH analogue). The research published on it covers rat, human and cell-culture work. Borealis Peptides keeps it in 10 mg vials of lyophilised powder for in-vitro laboratory research. It is not a medicine and is not for use in humans or animals. Each reference here appears alongside the model it was run in and the result as it was published.
Where can I buy Melanotan I in Canada?
Borealis Peptides dispatches Melanotan I from Canadian stock to research and business addresses within Canada, kept in 10 mg vials. HPLC testing covers every batch, and the certificate identifies the batch sitting in your vial. Only laboratory-research orders are accepted.
Is Melanotan I legal in Canada?
Canada has no authorized melanotan-1 product. Searching the Drug Product Database for melanotan brings up afamelanotide (SCENESSE, DIN 02569825), a separate molecule entirely. No authorized Melanotan I product therefore exists in Canada. Borealis Peptides provides it as research material for in-vitro laboratory use only. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we read it only as what the material is for, not a green light to use it.
How much Melanotan I should I use?
There is nothing to offer. Nothing on this site amounts to a protocol, a schedule or a reconstitution volume. The quantities in the cited studies belong to those studies and the models they were run in, and they appear here so the evidence can be judged instead of taken on trust.
What human evidence is there for Melanotan I?
Among the 8 cited studies, one is a controlled human trial and the remainder are animal or cell work. Every row states its model, the quantity used and what the authors reported, letting each study be weighed directly rather than via a summary.
How is Melanotan I stored?
While sealed, hold it at −20 °C away from light. Reconstituted, it is kept at 2–8 °C. The dry powder is unharmed by ambient transit and should go into the fridge once it arrives. A lyophilised peptide is degraded by light and temperature cycling, not by how long it spends in transit.
How is the purity of Melanotan I confirmed?
HPLC testing is done on every batch before sale, and the certificate points to the batch in your vial rather than to the product line as a whole. Filing that batch number with your records is what lets an observation be reproduced later. Certificates can be requested at any time.
How does Melanotan I compare with Melanotan II and PT-141?
These are distinct compounds with distinct published records, and no ranking is offered here. Melanotan II and PT-141 carry 8 cited studies and 8 cited studies on their page against 8 here. The comparison worth making is to read both tables alongside the models each one used.







